Skip to main content
Contact Us
Subscribe
E-Edition
51°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Reviva Pharmaceuticals Hldg Inc
(NQ:
RVPH
)
1.240
UNCHANGED
Streaming Delayed Price
Updated: 1:49 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
484,285
Open
1.250
Bid (Size)
1.230 (2)
Ask (Size)
1.240 (14)
Prev. Close
1.240
Today's Range
1.020 - 1.280
52wk Range
0.6000 - 5.670
Shares Outstanding
22,650,266
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Thursday's After-Market Session
October 24, 2024
Via
Benzinga
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
October 07, 2024
The FDA's approval of Bristol Myers Squibb's Cobenfy for schizophrenia opens doors for Reviva's brilaroxazine, a multi-receptor antipsychotic.
Via
Benzinga
Exposures
Product Safety
Performance
YTD
-76.65%
-76.65%
1 Month
-13.89%
-13.89%
3 Month
+37.79%
+37.79%
6 Month
-14.48%
-14.48%
1 Year
-72.63%
-72.63%
More News
Read More
RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q2 2024
August 14, 2024
Via
InvestorPlace
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
May 16, 2024
Via
NewMediaWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
May 16, 2024
Via
TheNewswire.com
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
RVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024
May 14, 2024
Via
InvestorPlace
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH
May 14, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
May 13, 2024
Via
NewMediaWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPH
May 13, 2024
Via
TheNewswire.com
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
12 Health Care Stocks Moving In Thursday's Intraday Session
May 09, 2024
Via
Benzinga
RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH
April 25, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
REVIVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reviva Pharmaceuticals Holdings, Inc. on Behalf of Reviva Stockholders and Encourages Investors to Contact the Firm
April 25, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
RVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023
April 15, 2024
Via
InvestorPlace
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
January 23, 2024
Via
InvestorPlace
Reviva to Present at Webull LIVE! Healthcare Webinar on January 17
January 10, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 22, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
December 18, 2023
Via
Benzinga
Life Science Investor Forum: Presentations Now Available for Online Viewing
December 15, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Science Investor Forum Agenda Announced for December 14th, 2023
December 12, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum
December 11, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
Analyst Assessment On Reviva Pharmaceuticals' Positive Schizophrenia Trial Data - Sees More Than 200% Upside In Stock
October 30, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
October 30, 2023
Via
Benzinga
Could This Be A Breakthrough in Mental Health? Reviva's Schizophrenia Drug Shows Promising Results In Key Trial
October 30, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
October 30, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
October 27, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
